Predict your next investment

Venture Capital
inimiti.net

See what CB Insights has to offer

Investments

20

Portfolio Exits

3

Funds

1

About Inimiti Capital Partners

Inimiti is an Israeli venture capital firm focused on software platforms and services in the New Media space (Internet, Mobile and anything in between).

Inimiti Capital Partners Headquarters Location

Kibbutz Glil-Yam PO Box 163

Herzliya, 46905,

Israel

972-9-951-7755

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Inimiti Capital Partners News

Genoox Raises $6 Million in Funding to Fuel Expansion Into U.S. Healthcare Market

Jul 11, 2017

Carbon Health Raises .5M to Launch Its Mobile Connected Healthcare Network Today, Genoox , the genomic analysis company on a mission to make it easier and more affordable for doctors, clinicians and researchers to improve patient outcomes using big data, announced a $6 million investment led by Inimiti Capital Partners and Glilot Capital Partners, one of the world’s highest performing early stage funds. A number of private investors from the genetic field also participated. The new capital will be used to expedite their genomic services and provide medical facilities with innovative solutions to help solve real and pressing healthcare problems in the U.S. Genoox is part of a new breed of emerging tech companies in the healthcare space focused on solving problems at the core of patient management. With the expansion into the U.S. market, Genoox will help medical facilities integrate clinical genetic sequencing data into their patient workflow by providing the most modern data mining and analysis technologies. Genoox is unique in its ability to simplify data management and interpretation, driving broader adoption of genomic information in patient treatment decisions by accelerating the collection, analysis and application of genetic sequencing data worldwide. For clinicians, Genoox creates value by translating complex genetic data into specific, actionable insights that can be shared with the patient. “With healthcare costs on the rise, and the question of who is responsible for those costs are on the minds of every American, Genoox wants to make it easier and more cost effective for medical providers to identify the genetic root cause of diseases and medical conditions. Rapid genetic diagnosis can help avoid a costly and frustrating diagnostic odyssey for the patient by enabling providers to treat patients in a faster, more accurate, cost-effective manner,” said Amir Trabelsi, CEO and co-founder of Genoox. “It is possible to lower costs while providing better medical treatments if clinicians and researchers have the right tools required to understand the vast amount of genetic information they are collecting. We help them to process the information, using our platform of genetic applications, in minutes rather than the old standard of hours or even days. Genoox can also reduce the current costs of clinical sequencing by up to 90% while maintaining high sensitivity and accuracy.” Clinical diagnostics in the U.S. represents about 2% of healthcare spend, yet drives nearly 70% of clinical treatment decisions. Genoox is tackling issues at the core of healthcare by combining a deep understanding of science with vigorous data analytics to lower costs and improve patient outcomes. “Genoox offers more accurate disease detection at a lower cost, making NGS more useful and available to all,” said Arik Kleinstein, co-founder and managing partner of Glilot Capital Partners. “Currently, clinical NGS is limited to academic centers and expensive specialty labs. The Genoox model will help to make cutting-edge genetic science available to community medical centers and underserved global markets. We believe that this is a game changer.” “With clinical sequencing still in its early days, we believe Genoox is positioned to become the clinical ‘operating system’ for NGS samples,” said Alon Geva, general partner at Inimiti Capital Partners. “The ability of the Genoox platform to translate complex data into clinical answers in a rapid, cost-effective way will help to make NGS available to the everyday patient.” Genoox works with a variety of leading medical centers and pharmaceutical companies, providing faster and more accurate genomic testing results. In 2017, Genoox was chosen as a partner of the Israeli government, tapped to analyze the genetic sequencing of more than 100,000 citizens. About Genoox Genoox is a genomic analysis company on a mission to make clinical genetic sequencing more accessible and affordable. Using its cloud-based platform, Genoox manages the entire genetic sequencing process from raw data collection to the delivery of clinical actionable insights. By automating data interpretation and providing millions of in-house and public data points through a proprietary search engine, Genoox aims to improve patient outcomes with increased accuracy and efficiency, enabling personalized medicine. Users across research, clinical and medical facilities can then securely share complex clinical research using a set of customizable tools developed to analyze data and generate actionable reports. Genoox has an international footprint, with a U.S. presence in Palo Alto and New York City. The company was co-founded by Amir Trabelsi and Moshe Einhorn in 2014. View source version on businesswire.com: http://www.businesswire.com/news/home/20170711005792/en/ Moxie Communications Group

Inimiti Capital Partners Investments

20 Investments

Inimiti Capital Partners has made 20 investments. Their latest investment was in Craft.io as part of their Series A on November 11, 2021.

CBI Logo

Inimiti Capital Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/18/2021

Series A

Craft.io

$8M

Yes

5

6/3/2021

Series C

Genoox

$8M

No

1

6/20/2018

Series A

TinyTap

$5M

No

3

5/15/2018

Series B

Subscribe to see more

$99M

Subscribe to see more

10

5/1/2018

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/18/2021

6/3/2021

6/20/2018

5/15/2018

5/1/2018

Round

Series A

Series C

Series A

Series B

Series B

Company

Craft.io

Genoox

TinyTap

Subscribe to see more

Subscribe to see more

Amount

$8M

$8M

$5M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

1

3

10

10

Inimiti Capital Partners Portfolio Exits

3 Portfolio Exits

Inimiti Capital Partners has 3 portfolio exits. Their latest portfolio exit was TinyTap on June 16, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/16/2022

Corporate Majority

$99M

1

12/11/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

1/13/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/16/2022

12/11/2019

1/13/2015

Exit

Corporate Majority

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Inimiti Capital Partners Fund History

1 Fund History

Inimiti Capital Partners has 1 fund, including Inimiti Capital Partners I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/14/2014

Inimiti Capital Partners I

Multi-Stage Venture Capital

Open

$30.11M

1

Closing Date

2/14/2014

Fund

Inimiti Capital Partners I

Fund Type

Multi-Stage Venture Capital

Status

Open

Amount

$30.11M

Sources

1

Inimiti Capital Partners Team

5 Team Members

Inimiti Capital Partners has 5 team members, including current Chief Financial Officer, Lilach Peer.

Name

Work History

Title

Status

Lilach Peer

Chief Financial Officer

Current

Alon Geva

General Partner

Current

Nimrod Lev

General Partner

Current

Nimrod Lev

MySpace, Fox Interactive Media, and Walla!

General Partner

Current

Ofer Timor

General Partner

Current

Name

Lilach Peer

Alon Geva

Nimrod Lev

Nimrod Lev

Ofer Timor

Work History

MySpace, Fox Interactive Media, and Walla!

Title

Chief Financial Officer

General Partner

General Partner

General Partner

General Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.